Retrospective Case Series Analysis of

In pancreatic cancer (PC), the Clinical outcomes were assessed across a multi-institutional case series of 81 patients with The frequency of RAF alterations in PC was 2.2% (84 of 3,781) within a prevalence cohort derived from large molecular databases where Prospective evaluation of

Informations de copyright

© 2021 by American Society of Clinical Oncology.

Déclaration de conflit d'intérêts

Andrew Hendifar Consulting or Advisory Role: Novartis, Ipsen, Perthera, Celgene, AbbVie, Eisai Research Funding: Ipsen, NGM Biopharmaceuticals Travel, Accommodations, Expenses: Halozyme Edik M. Blais Employment: AstraZeneca, Perthera, Emerald Cloud Labs Stock and Other Ownership Interests: Perthera Patents, Royalties, Other Intellectual Property: Named as an inventor on patents filed by Perthera Inc (as an employee) Brian Wolpin Honoraria: G1 Therapeutics, Celgene Consulting or Advisory Role: Genentech, G1 Therapeutics, BioLineRx, GRAIL, Celgene Research Funding: Celgene, Lilly Vivek Subbiah Consulting or Advisory Role: MedImmune, Helsinn Therapeutics, Loxo, R-Pharm, QED Therapeutics Research Funding: Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, AbbVie, Multivir, Blueprint Medicines, LOXO, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Turning Point Therapeutics Travel, Accommodations, Expenses: PharmaMar, Bayer, Novartis, Helsinn Therapeutics Other Relationship: Medscape Eric Collisson Stock and Other Ownership Interests: Guardant Health, BloodQ, Tatara Therapeutics, Clara Health, Hint Health Consulting or Advisory Role: Merck Research Funding: Merck KGaA, Loxo/Bayer, Ferro Oncology/Bridge Bio, AstraZeneca Expert Testimony: NantBioScience Inc Timothy Cannon Honoraria: Deciphera, AstraZeneca Consulting or Advisory Role: Loxo, Navican Other Relationship: Navican/Intermountain Healthcare Kenna Shaw Consulting or Advisory Role: Guidepoint Global Research Funding: Guardant Health, Tempus, Philips Healthcare Emanuel F. Petricoin Leadership: Perthera, Ceres Nanosciences Stock and Other Ownership Interests: Perthera, Ceres Nanosciences, Theralink Technologies, Inc Consulting or Advisory Role: Perthera, Ceres Nanosciences, TheraLink Technologies, Inc Research Funding: Ceres Nanosciences, AbbVie, Mirati Therapeutics, Genentech, G1 Therapeutics Patents, Royalties, Other Intellectual Property: NIH Patents Licensing Fee Distribution/Royalty, University assigned patent licensing fee/royalty Travel, Accommodations, Expenses: Perthera, Ceres Nanosciences Samuel Klempner Stock and Other Ownership Interests: TP Therapeutics Honoraria: Natera Consulting or Advisory Role: Lilly, Boston Biomedical, Astellas Pharma, Foundation Medicine, Bristol Myers Squibb, Pieris Pharmaceuticals, Merck, Daiichi Sankyo/UCB Japan Speakers' Bureau: Foundation Medicine Research Funding: Leap Therapeutics, BeiGene Other Relationship: NCCN Emily Lyons Research Funding: Midwinter Solutions, Repare Therapeutics, InVitae, Novocure, AstraZeneca, NCgenetics, Indegene, 2nd.MD, Novartis, Ipsen, Engitix, Abbott, BiolineRx, Speratum, Phase V Consulting, Amarex Clinical Research, RenovoRx, Merck, FibroGen Andrea Wang-Gillam Employment: Jacobio Stock and Other Ownership Interests: Jacobio Consulting or Advisory Role: Jacobio, AstraZeneca, Repugene, Merck, Eisai, Bayer, Inxmed Research Funding: AstraZeneca, Pfizer, Lilly, Verastem, Merck, BioMed Valley Discoveries, Roche, Bristol Myers Squibb, Xcovery, Boston Biomedical, Hutchison MediPharma, Rafael Pharmaceuticals, Gossamer Bio Michael J. Pishvaian Stock and Other Ownership Interests: Perthera Honoraria: Halozyme Consulting or Advisory Role: Perthera, AstraZeneca/MedImmune, Merck Research Funding: Tesaro, Seattle Genetics, Pfizer Patents, Royalties, Other Intellectual Property: Perthera patient matching algorithm, Use patent for veliparib and FOLFOX Eileen M. O'Reilly Consulting or Advisory Role: Adicet Bio, Agios, AstraZeneca, Alnylam, Autem Medical, Bayer, BeiGene, Berry Genomics, Center for Emerging & Neglected Diseases (CEND), Celgene, CytomX Therapeutics, Eisai, Exelixis, Flatiron Health, Genentech/Roche, Genoscience Pharma, Helio, Incyte, Ipsen, Legend Biotech, Loxo, Merck, MiNA Therapeutics, Nerviano Medical Sciences, QED Therapeutics, RedHill Biopharma, Refael, Silenseed, Sillajen, SOBI, Surface Oncology, TheraBionic, twoXAR, Vector Health, Yiviva Research Funding: AstraZeneca/MedImmune, Celgene, Genentech, Roche, Silenseed, Arcus Ventures, BioNTech AG No other potential conflicts of interest were reported. Andrew Hendifar Consulting or Advisory Role: Novartis, Ipsen, Perthera, Celgene, AbbVie, Eisai Research Funding: Ipsen, NGM Biopharmaceuticals Travel, Accommodations, Expenses: Halozyme Edik M. Blais Employment: AstraZeneca, Perthera, Emerald Cloud Labs Stock and Other Ownership Interests: Perthera Patents, Royalties, Other Intellectual Property: Named as an inventor on patents filed by Perthera Inc (as an employee) Brian Wolpin Honoraria: G1 Therapeutics, Celgene Consulting or Advisory Role: Genentech, G1 Therapeutics, BioLineRx, GRAIL, Celgene Research Funding: Celgene, Lilly Vivek Subbiah Consulting or Advisory Role: MedImmune, Helsinn Therapeutics, Loxo, R-Pharm, QED Therapeutics Research Funding: Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, AbbVie, Multivir, Blueprint Medicines, LOXO, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Turning Point Therapeutics Travel, Accommodations, Expenses: PharmaMar, Bayer, Novartis, Helsinn Therapeutics Other Relationship: Medscape Eric Collisson Stock and Other Ownership Interests: Guardant Health, BloodQ, Tatara Therapeutics, Clara Health, Hint Health Consulting or Advisory Role: Merck Research Funding: Merck KGaA, Loxo/Bayer, Ferro Oncology/Bridge Bio, AstraZeneca Expert Testimony: NantBioScience Inc Timothy Cannon Honoraria: Deciphera, AstraZeneca Consulting or Advisory Role: Loxo, Navican Other Relationship: Navican/Intermountain Healthcare Kenna Shaw Consulting or Advisory Role: Guidepoint Global Research Funding: Guardant Health, Tempus, Philips Healthcare Emanuel F. Petricoin Leadership: Perthera, Ceres Nanosciences Stock and Other Ownership Interests: Perthera, Ceres Nanosciences, Theralink Technologies, Inc Consulting or Advisory Role: Perthera, Ceres Nanosciences, TheraLink Technologies, Inc Research Funding: Ceres Nanosciences, AbbVie, Mirati Therapeutics, Genentech, G1 Therapeutics Patents, Royalties, Other Intellectual Property: NIH Patents Licensing Fee Distribution/Royalty, University assigned patent licensing fee/royalty Travel, Accommodations, Expenses: Perthera, Ceres Nanosciences Samuel Klempner Stock and Other Ownership Interests: TP Therapeutics Honoraria: Natera Consulting or Advisory Role: Lilly, Boston Biomedical, Astellas Pharma, Foundation Medicine, Bristol Myers Squibb, Pieris Pharmaceuticals, Merck, Daiichi Sankyo/UCB Japan Speakers' Bureau: Foundation Medicine Research Funding: Leap Therapeutics, BeiGene Other Relationship: NCCN Emily Lyons Research Funding: Midwinter Solutions, Repare Therapeutics, InVitae, Novocure, AstraZeneca, NCgenetics, Indegene, 2nd.MD, Novartis, Ipsen, Engitix, Abbott, BiolineRx, Speratum, Phase V Consulting, Amarex Clinical Research, RenovoRx, Merck, FibroGen Andrea Wang-Gillam Employment: Jacobio Stock and Other Ownership Interests: Jacobio Consulting or Advisory Role: Jacobio, AstraZeneca, Repugene, Merck, Eisai, Bayer, Inxmed Research Funding: AstraZeneca, Pfizer, Lilly, Verastem, Merck, BioMed Valley Discoveries, Roche, Bristol Myers Squibb, Xcovery, Boston Biomedical, Hutchison MediPharma, Rafael Pharmaceuticals, Gossamer Bio Michael J. Pishvaian Stock and Other Ownership Interests: Perthera Honoraria: Halozyme Consulting or Advisory Role: Perthera, AstraZeneca/MedImmune, Merck Research Funding: Tesaro, Seattle Genetics, Pfizer Patents, Royalties, Other Intellectual Property: Perthera patient matching algorithm, Use patent for veliparib and FOLFOX Eileen M. O'Reilly Consulting or Advisory Role: Adicet Bio, Agios, AstraZeneca, Alnylam, Autem Medical, Bayer, BeiGene, Berry Genomics, Center for Emerging & Neglected Diseases (CEND), Celgene, CytomX Therapeutics, Eisai, Exelixis, Flatiron Health, Genentech/Roche, Genoscience Pharma, Helio, Incyte, Ipsen, Legend Biotech, Loxo, Merck, MiNA Therapeutics, Nerviano Medical Sciences, QED Therapeutics, RedHill Biopharma, Refael, Silenseed, Sillajen, SOBI, Surface Oncology, TheraBionic, twoXAR, Vector Health, Yiviva Research Funding: AstraZeneca/MedImmune, Celgene, Genentech, Roche, Silenseed, Arcus Ventures, BioNTech AG No other potential conflicts of interest were reported.